Nova Eye Medical Ltd. engages in developing suite of novel ophthalmic treatment technologies. The company is headquartered in Adelaide, South Australia. The Company’s principal activities include design, development, service and marketing, sales, and distribution of medical devices to treat eye disease. The Company’s segments include 2RT and Glaucoma surgical devices. The firm’s 2RT is an ophthalmic laser developed for the therapy of patients in the early to intermediate stages of age-related macular degeneration (AMD). Its technology includes the iTrack portfolio of canaloplasty devices for the treatment of glaucoma. iTrack minimally invasive glaucoma surgery (MIGS) is an implant-free, tissue-sparing device. iTrack is performed via an ab-externo approach to offer a bleb-free alternative to traditional glaucoma surgery in the treatment of advanced glaucoma patients. The firm also manufactures and sells the proprietary Molteno3 glaucoma drainage device for the treatment of severe or complex glaucoma.
Nova Eye Medical (ASX: EYE)
- Home
- Nova Eye Medical (ASX: EYE)
Here are the latest articles on Nova Eye Medical (ASX: EYE)
Nova Eye Medical reports surge in USA sales despite Medicare reimbursement uncertainty
January 9, 2024
Aussie MedTech company Nova Eye Medical (ASX: EYE) has kicked off the new year with good news for investors, recording an impressive $7.6 million in sales in the US for its glaucoma surgical devices during the six months concluding on December 31, 2023 (unaudited). This represents a remarkable 65% growth compared to the previous corresponding
Nova’s Glaucoma surgical device iTrack Advance has its eyes set on FDA approval
November 16, 2022
Over 100 million people worldwide suffer from glaucoma—a cocktail of eye infections resulting in blindness. Though glaucoma has no cure, some treatments can aid vision loss, slowing down its progression or intensity. One such treatment is MedTech company Nova Eye Medical’s (ASX: EYE) glaucoma surgical devices, which witnessed sales revenue of $5.66 million between July
Nova Eye Health sees immediate sales of glaucoma surgery device following regulatory approvals
July 8, 2022
With improvements in allied healthcare, the 134 million people worldwide diagnosed with glaucoma is likely to increase with better diagnostics, but also ensure earlier detection which can be treated sooner as evidenced by medtech company Nova Eye Medical (ASX: EYE) and rising sales of their advanced ophthalmic treatment technologies and devices. As the developers and
Recent Articles
